Consumer doesn't count for sh$t. Don't pay attention to the revenue line - how many times does your finance teacher have to tell you that? Free Cash Flow! Those stents have big fat margins on them while the consumer revenue does not. (Same with the pharma group - fat margins). The revenue from those stents will grow quickly but it's the earnings and cash flow from those babies that you need to look at.
My belief is that doctors will look at the pricing since none of the data is a slam dunk yet. If there is a pricing war nobody wins. However, I will conisder shorting BSX since 75% of their future growth multiple rests in those stents and if there is a price war, they will have some issues.